Current stock page

Catalysts

EW Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - DevicesScore data as of Sep 4, 2026

EW

Catalysts
Edwards Lifesciences Corporation
Healthcare· Medical - Devices
AIQ Score
NeutralAIQ Edge 7/10
Low Priority
Above Peers
Score data as of Sep 4, 2026
Last price
$89.90
+$0.12 (+0.13%)
Latest market quote
Momentum56
Value28
Quality69
Risk Resilience80
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Oct 29, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 55/100

Momentum 56/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 29.38%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 56/100AIQ Edge 7/10 Above Peers
Beat rate
88%
7 of 8 reported periods
Average surprise
+5.1%
Across covered historical reports
Latest result
+5.0%
Jul 23, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Jul 23, 2026$0.74$0.78+5.0%$1.7B$1.74B
Apr 23, 2026$0.73$0.78+7.0%$1.6B$1.65B
Feb 10, 2026$0.62$0.58-6.1%$1.55B$1.57B
Oct 30, 2025$0.60$0.67+12.4%$1.5B$1.55B
Jul 24, 2025$0.62$0.67+7.4%$1.49B$1.53B
Apr 23, 2025$0.60$0.64+7.4%$1.4B$1.41B
Feb 11, 2025$0.55$0.59+7.1%$1.36B$1.39B
Oct 24, 2024$0.67$0.67+0.8%$1.54B$1.35B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
22
Buy
7
Hold
12-month analyst target
$100.00
+11.23% versus current price
Based on 10 analyst observations. Targets are estimates, not predictions.
Low target
$85.00
-5.45% vs latest price
Average target
$100.00
+11.23% vs latest price
High target
$110.00
+22.36% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateOct 29, 2026

Next known earnings or reporting date.

EPS estimate$0.73

Current analyst expectation for the upcoming report.

Revenue estimate$1.68B

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score56

Where event reaction would show up first.

AIQ score55/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
10
Average target
$100.00
Target upside
11.23%
Target range
$85.00 - $110.00
90-day revisions
1

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
gurufocus.com · Aug 29, 2026

Edwards Lifesciences (EW) Announces Retirement of Corporate Vice President Donald E. Bobo Jr.

Edwards Lifesciences Corporation (EW) announced Monday that Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, has informed th

finance.yahoo.com · Aug 28, 2026

Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]

seekingalpha.com · Aug 12, 2026

Edwards Lifesciences: Strong Execution, But Little Room For Error At $90 (NYSE:EW)

Edwards Lifesciences is rated Sell with a $77 price target, reflecting limited upside versus the recent $89.72 close. Click for my latest analysis of EW stock.

seekingalpha.com · Aug 12, 2026

Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW)

Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.

finance.yahoo.com · Aug 4, 2026

Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Open full news and sentiment

EW Catalysts FAQ

What are the next catalysts for EW stock?

EW's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move EW stock?

Upcoming events that could move EW include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could EW's next earnings report affect the stock?

EW's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive EW stock higher?

EW could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt EW stock?

EW could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.